Clinical Trials on B-ALL in Belgium

Total 12122 results

Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Novartis Vaccines
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

Group B Streptococcus

Belgium
GlaxoSmithKline

Completed

A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays

Immunologic Tests

Belgium
GlaxoSmithKline

Completed

Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)

Hepatitis B Disease

Belgium
Allogene Therapeutics

Active, not recruiting

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPAND)

Relapsed/Refractory Large B Cell Lymphoma

United States, Belgium
Universitaire Ziekenhuizen KU Leuven

Unknown

Genomic Analysis of Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Belgium
Lymphoma Study Association
Fondation ARC

Completed

ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Belgium
The Lymphoma Academic Research Organisation
Karyopharm Therapeutics Inc

Completed

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP (SELINDA)

B-cell Lymphoma

Belgium, France
Universitaire Ziekenhuizen KU Leuven
KU Leuven

Unknown

Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates

Pharmacokinetics | Critically Ill Patients | Liposomal Amphotericin B

Belgium
Cliniques universitaires Saint-Luc- Université...

Completed

Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy

Haemophilia A | Haemophilia B

Belgium
Advancell - Advanced In Vitro Cell Technologies...
Nexus Oncology Ltd

Completed

Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients

Leukemia, B-Cell, Chronic

Spain, France, Belgium
Lymphoma Study Association
Amgen

Completed

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Diffuse Large-Cell Lymphoma

France, Belgium
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
The Lymphoma Academic Research Organisation
Pfizer

Completed

Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse

Diffuse Large B-Cell Lymphoma

France, Belgium
GlaxoSmithKline

Completed

Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.

Streptococcus Agalactiae | Bacterial Infection Due to Streptococcus, Group B

Belgium
Minervax ApS
Iqvia Pty Ltd

Completed

Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants

Group B Streptococcal Infections

Belgium
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
Lymphoma Study Association
Amgen

Terminated

ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Lymphoma Study Association

Completed

ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
The Lymphoma Academic Research Organisation

Recruiting

Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older

DLBCL

France, Belgium
Lymphoma Study Association
Amgen

Completed

R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma

Diffuse Large Cell Lymphoma

France, Belgium, Switzerland
Boehringer Ingelheim

Completed

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Lymphoma, Large B-Cell, Diffuse

Spain, Italy, Belgium
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

Hepatitis B

Belgium
Bristol-Myers Squibb

Recruiting

Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Secondary Malignancy

Multiple Myeloma | Non-Hodgkin Lymphoma | Chronic Lymphocytic Leukaemia

Belgium
Novartis Pharmaceuticals

Recruiting

Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

B-cell Non-Hodgkin Lymphoma (B-NHL) | B-cell Acute Lymphoblastic Leukemia (B-ALL)

Japan, Italy, Spain, Belgium, Singapore, France, United States, Israel
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B

Chronic Hepatitis B

Belgium, Germany, United Kingdom, Philippines
GlaxoSmithKline

Completed

Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B

Hepatitis B Vaccine

Belgium, Canada
Merck KGaA, Darmstadt, Germany

Completed

Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Advanced Solid Tumors

Belgium, Netherlands, Denmark
Grand Hôpital de Charleroi

Recruiting

Prospective Observational Study of Diffuse Large-cell B Lymphoma (LBDGCréfract)

Lymphoma, B-Cell

Belgium
Sarah Saxena
CHU de Charleroi

Completed

The Thiamine Administration After Cardiac Surgery Trial (TAACS)

Lactate Blood Increase | Thiamine Deficiency

Belgium
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Active, not recruiting

Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

Primary Mediastinal Large B Cell Lymphoma

France, Belgium, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain
GlaxoSmithKline

Completed

Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers

Hepatitis B

Belgium
Institute of Tropical Medicine, Belgium
University Hospital, Antwerp

Completed

COVID-19 Immune Repertoire Sequencing (IMSEQ)

SARS-CoV 2 | COVID | Corona Virus Infection | RDT | B Cell

Belgium
Novosanis NV

Completed

Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID (POC_VAX-ID)

Hepatitis B

Belgium
The Lymphoma Academic Research Organisation

Active, not recruiting

Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

B-cell Lymphoma Recurrent | B-Cell Lymphoma Refractory

France, Belgium
Lymphoma Study Association

Completed

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

United States, Australia, Belgium, Czechia, Finland, Germany, Israel, Sweden, Switzerland, United Kingdom
Merus N.V.
Incyte Corporation

Recruiting

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Advanced Cancer | Solid Tumor, Adult | B-cell Lymphoma, Adult

United States, Spain, Belgium, Netherlands
Lymphoma Study Association

Completed

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

B-Cell Lymphoma

France, Belgium, Switzerland
ANRS, Emerging Infectious Diseases
INSERM SC10-US19

Recruiting

Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load (SYNACTHIV)

HIV-1-infection, Subtype b

Belgium, France
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Hepatitis B

Denmark, Belgium
GlaxoSmithKline

Completed

Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline

Completed

Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Cliniques universitaires Saint-Luc- Université...

Unknown

Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)

Chronic Lymphocytic Leukemia

Belgium
GlaxoSmithKline

Completed

Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule

Hepatitis B | Hepatitis A

Belgium
GlaxoSmithKline
Region of Wallonia; Public Private Partnership with Institute for Medical Immunology...

Completed

Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System

Hepatitis B

Belgium

3

Subscribe